Recombinant Human CD59 (C-6His)

Description

EnkiLife provides the Recombinant Human CD59 (C-6His) protein,aslo know as 1F5 antigen,1F5,20 kDa homologous restriction factor,CD59 antigen,CD59 glycoprotein,CD59,HRF20,HRF-20,MACIF,MAC-IP,MIC11,MIC11MSK21,MIN1,MIN2,MIN3,MIRL,p18-20,16.3A5,EL32,FLJ38134,FLJ92039,G344, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human CD59 Glycoprotein is produced by our Mammalian expression system and the target gene encoding Leu26-Asn102 is expressed with a 6His tag at the C-terminus.Accession:P13987. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:9.8 KDa. Background:CD59, also known as membrane attack complex inhibition factor (MACIF), Protectin, 1F5 antigen, HRF-20 and MIRL, is an approximately 20 kDa GPI anchored glycoprotein that is an important regulator of the complement system in blood. CD59 is a potent inhibitor of the complement membrane attack complex (MAC) action. CD59 was first identified as a regulator of the terminal pathway of complement. It acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. CD59 is involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.